Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PTEN |
Variant | Q245* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | PTEN Q245* results in a premature truncation of the Pten protein at amino acid 245 of 403 (UniProt.org). Q245* results in reduced phosphatase activity in a yeast assay (PMID: 29706350), and therefore, is predicted to lead to a loss of Pten protein function. |
Associated Drug Resistance | |
Category Variants Paths |
PTEN mutant PTEN inact mut PTEN Q245* |
Transcript | NM_000314.8 |
gDNA | chr10:g.87957951C>T |
cDNA | c.733C>T |
Protein | p.Q245* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000314.8 | chr10:g.87957951C>T | c.733C>T | p.Q245* | RefSeq | GRCh38/hg38 |
NM_000314 | chr10:g.87957951C>T | c.733C>T | p.Q245* | RefSeq | GRCh38/hg38 |
NM_000314.6 | chr10:g.87957951C>T | c.733C>T | p.Q245* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN Q245* | lung squamous cell carcinoma | sensitive | Buparlisib + Carboplatin + Paclitaxel | Preclinical - Pdx | Actionable | In a preclinical study, the addition of Buparlisib (BKM120) to treatment with the combination of Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in improved tumor growth inhibition compared to chemotherapy or Buparlisib (BKM120) alone in a patient-derived xenograft (PDX) model of squamous non-small cell lung cancer harboring PTEN Q245* (PMID: 39199558). | 39199558 |
PTEN Q245* | lung squamous cell carcinoma | sensitive | Carboplatin + Paclitaxel + Vistusertib | Preclinical - Pdx | Actionable | In a preclinical study, the addition of Vistusertib (AZD2014) to treatment with the combination of Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in improved tumor growth inhibition compared to chemotherapy or Buparlisib (BKM120) alone in a patient-derived xenograft (PDX) model of squamous non-small cell lung cancer harboring PTEN Q245* (PMID: 39199558). | 39199558 |